459434-40-3

Usage

Uses

Used in Pharmaceutical Industry:
3-Amino-N-methylbenzenesulfonamide is used as an active pharmaceutical ingredient for its antibiotic properties, contributing to the development of medications that combat bacterial infections.
Used in Agricultural Industry:
In agriculture, 3-Amino-N-methylbenzenesulfonamide is used as a component in the formulation of agrochemicals, specifically for its antimicrobial effects to protect crops from bacterial diseases.
Used in Dye Industry:
3-Amino-N-methylbenzenesulfonamide is used as a chemical intermediate in the dye industry, where its unique chemical structure aids in the synthesis of various dyes and pigments.
Used in Other Industries:
3-Amino-N-methylbenzenesulfonamide's applications extend to other industries where its chemical properties are leveraged for specific purposes, such as in the synthesis of certain types of chemicals or materials.

InChI:InChI=1/C7H10N2O2S/c1-9-12(10,11)7-4-2-3-6(8)5-7/h2-5,9H,8H2,1H3

Upstream product

• 58955-78-5 N-methyl-3-nitrobenzenesulfonamide 
• 121-51-7 3-nitrobenzenesulphonyl chloride 
• 89599-01-9 3-bromobenzenesulfonamide 
• 153435-79-1 N-methyl-3-bromobenzenesulfonamide 

Downstream Products

• 1028253-56-6 3-methyl-N-(3-(methylsulfamoyl)phenyl)-D-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide 
• 1028253-55-5 3-methyl-N-(3-(methylsulfamoyl)phenyl)-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide 
• 1315512-70-9 3-({4-[(4-chlorophenyl)amino]-1,3,5-triazin-2-yl}amino)-N-methylbenzenesulfonamide 
• 1315512-69-6 N-methyl-3-({4-[(3-methylphenyl)amino]-1,3,5-triazin-2-yl}amino)benzenesulfonamide 
• 1351089-89-8 N-methyl-3-[(5-methyl-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]benzenesulfonamide 
• 1300026-86-1 4-({3-[(methylamino)sulfonyl]phenyl}amino)-9H-pyrimido[4,5-b]indol-7-carboxylic acid 
• 1315512-77-6 3-{[4-({3-[(methylamino)sulfonyl]phenyl}amino)-1,3,5-triazin-2-yl]amino}benzamide trifluoroacetate 
• 1315512-76-5 3-{[4-({3-[(methylamino)sulfonyl]phenyl}amino)-1,3,5-triazin-2-yl]amino}benzamide 
• 57946-88-0 N-Methyl-3-trifluoromethanesulfonylamino-benzenesulfonamide 

Relevant academic research and scientific papers

N-Methylation of Amines with Methanol in the Presence of Carbonate Salt Catalyzed by a Metal-Ligand Bifunctional Ruthenium Catalyst [(p-cymene)Ru(2,2′-bpyO)(H2O)]

A ruthenium complex [(p-cymene)Ru(2,2′-bpyO)(H2O)] was found to be a general and efficient catalyst for the N-methylation of amines with methanol in the presence of carbonate salt. Moreover, a series of sensitive substituents, such as nitro, ester, cyano, and vinyl groups, were tolerated under present conditions. It was confirmed that OH units in the ligand are crucial for the catalytic activity. Notably, this research exhibited the potential of metal-ligand bifunctional ruthenium catalysts for the hydrogen autotransfer process.

SUBSTITUTED AMIDE COMPOUNDS USEFUL AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt or solvate thereof, wherein Q is: (i) halo, cyano, hydroxyl, NRxRx, C(O)OH, C(O)NH2, C1-6 alkyl substituted with zero to 6 R1a, or P(O)R1cR1c; or (ii) L R1; and A, X1, X2, X3, X4, Z1, Z2, R1, R1a, R1c, R2, R3a, R3b, Rx, L, a, b, and d are defined herein. Also disclosed are methods of using these compounds to modulate the activity of farnesoid X receptor (FXR); pharmaceutical compositions comprising these compounds; and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Method for preparing TNNI3K inhibitor (by machine translation)

The method TNNI3K comprises the following steps: heating the m-bromobenzene sulfonamide in the presence of an iridium complex catalyst and a base: for a few hours and then cooling to room temperature, to dry the solvent, to obtain, methyl - 3 3-aminobenze

Sulfonamide-based 4-anilinoquinoline derivatives as novel dual Aurora kinase (AURKA/B) inhibitors: Synthesis, biological evaluation and in silico insights

Aurora kinases (AURKs) were identified as promising druggable targets for targeted cancer therapy. Aiming at the development of novel chemotype of dual AURKA/B inhibitors, herein we report the design and synthesis of three series of 4-anilinoquinoline derivatives bearing a sulfonamide moiety (5a-d, 9a-d and 11a-d). The percent inhibition of AURKA/B was determined for all target quinolines, then compounds showed more than 50percent inhibition on either of the enzymes, were evaluated further for their IC50 on the corresponding enzyme. In particular, compound 9d displayed potent AURKA/B inhibitory activities with IC50 of 0.93 and 0.09 μM, respectively. Also, 9d emerged as the most efficient anti-proliferative analogue in the US-NCI anticancer assay toward the NCI 60 cell lines panel, with broad spectrum activity against different cell lines from diverse cancer subpanels. Docking studies, confirmed that, the sulfonamide SO2 oxygen was involved in a hydrogen bond with Lys162 and Lys122 in AURKA and AURKB, respectively, whereas, the sulfonamide NH could catch hydrogen bond interaction with the surrounding amino acid residues Lys141, Glu260, and Asn261 in AURKA and Lys101, Glu177, and Asp234 in AURKB. Furthermore, N1 nitrogen of the quinoline scaffold formed an essential hydrogen bond with the hinge region key amino acids Ala213 and Ala173 in AURKA and AURKB, respectively.

Synthetic TNNI3K inhibitors (by machine translation)

The invention discloses a method for synthesizing TNNI3K inhibitors, proceeding from interval tetrabromobensoate sulfonamides, containing double-imidazole ligand iridium complex and under the action of the weak catalytic activation methanol instead of high toxicity halogenated methane get methylation product, further with the ammonia generating uhlmann coupling reaction, the final with 4 - chloro-pyrrolo pyrimidine nucleophilic substitution reaction to obtain TNNI3K inhibitors. The present invention through the use of iridium metal complex as the methylation reaction catalyst, the reaction conditions are more moderate and high yield, without the need of high temperature and high pressure, nitrogen protection, severe conditions such as the reaction for a long time, the last step nucleophilic substitution reaction we adopt a microwave reactor greatly shorten the reaction time. (by machine translation)

Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino)benzenesulfonamidesAQ3 as carbonic anhydrase isoforms I and II inhibitors

Carbonic anhydrases (CAs, EC 4.2.1.1) are crucial metalloenzymes that are involved in diverse bioprocesses. We report the synthesis and biological evaluation of novel series of benzenesulfonamides incorporating un/substituted ethyl quinoline-3-carboxylate moieties. The newly synthesised compounds were in vitro evaluated as inhibitors of the cytosolic human (h) isoforms hCA I and II. Both isoforms hCA I and II were inhibited by the quinolines reported here in variable degrees: hCA I was inhibited with KIs in the range of 0.966–9.091 μM, whereas hCA II in the range of 0.083–3.594 μM. The primary 7-chloro-6-flouro substituted sulphfonamide derivative 6e (KI = 0.083 μM) proved to be the most active quinoline in inhibiting hCA II, whereas, its secondary sulfonamide analog failed to inhibit the hCA II up to 10 μM, confirming the crucial role of the primary sulphfonamide group, as a zinc-binding group for CA inhibitory activity.

N-Methylation of Amines with Methanol Catalyzed by a Cp?Ir Complex Bearing a Functional 2,2′-Bibenzimidazole Ligand

A new type of Cp?Ir complex bearing a functional 2,2′-bibenzimidazole ligand was designed, synthesized, and found to be a highly effective and general catalyst for the N-methylation of a variety of amines with methanol in the presence of a weak base (0.3 equiv of Cs2CO3).

METHODS FOR INHIBITING NECROPTOSIS

The present invention relates to methods for inhibiting necroptosis; screening methods for identifying compounds which inhibit necroptosis; and compounds for the inhibition of necroptosis, which may be useful in the treatment of conditions associated with deregulated necroptosis.

Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors

Screening of the NCI Diversity Set-1 identified PI-083 (NSC-45382) a proteasome inhibitor selective for cancer over normal cells. Focused libraries of novel compounds based on PI-083 chloronaphthoquinone and sulfonamide moieties were synthesized to gain a better understanding of the structure-activity relationship responsible for chymotrypsin-like proteasome inhibitory activity. This led to the demonstration that the chloronaphthoquinone and the sulfonamide moieties are critical for inhibitory activity. The pyridyl group in PI-083 can be replaced with other heterocyclic groups without significant loss of activity. Molecular modeling studies were also performed to explore the detailed interactions of PI-083 and its derivatives with the β5 and β6 subunits of the 20S proteasome. The refined model showed an H-bond interaction between the Asp-114 and the sulfonamide moiety of the PI-083 in the β6 subunit.